Literature DB >> 18465265

Permeability classification of representative fluoroquinolones by a cell culture method.

Donna A Volpe1.   

Abstract

This study was undertaken to categorize representative fluoroquinolone drug substance permeability based on the methods outlined in the Food and Drug Administration's biopharmaceutic classification system (BCS) Guidance for Industry. The permeability of ciprofloxacin, levofloxacin, lomefloxacin, and ofloxacin was measured in an in vitro Caco-2 assay with previously demonstrated method suitability. The permeability class and efflux potential were ascertained by comparing test drug results with standard compounds (metoprolol, atenolol, labetalol, and rhodamine-123). All 4 quinolones drugs demonstrated concentration-dependent permeability, indicating active drug transport. In comparing absorptive versus secretive in vitro transport, the tested fluoroquinolones were found to be subject to efflux in varying degrees (ciprofloxacin > lomefloxacin > rhodamine 123 > levofloxacin > ofloxacin). Based on comparison to labetalol, the high permeability internal standard, ciprofloxacin was classified as a low permeability drug, whereas lomefloxacin, levofloxacin, and ofloxacin were classified as high permeability drugs. The in vitro permeability results matched human in vivo data based on absolute bioavailabilities. This laboratory exercise demonstrated the applicability of an in vitro permeability method for classifying drugs as outlined in the BCS Guidance.

Entities:  

Year:  2004        PMID: 18465265      PMCID: PMC4859453          DOI: 10.1208/ps060213

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  11 in total

1.  Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies.

Authors:  M Rodríguez-Ibáñez; R Nalda-Molina; M Montalar-Montero; M V Bermejo; V Merino; T M Garrigues
Journal:  Eur J Pharm Biopharm       Date:  2003-03       Impact factor: 5.571

2.  Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.

Authors:  H Yamaguchi; I Yano; Y Hashimoto; K I Inui
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

Review 3.  Clinical use of the fluoroquinolones.

Authors:  R C Owens; P G Ambrose
Journal:  Med Clin North Am       Date:  2000-11       Impact factor: 5.456

Review 4.  Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.

Authors:  K E Pickerill; J A Paladino; J J Schentag
Journal:  Pharmacotherapy       Date:  2000-04       Impact factor: 4.705

5.  Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.

Authors:  H Yamaguchi; I Yano; H Saito; K Inui
Journal:  Eur J Pharmacol       Date:  2001-11-23       Impact factor: 4.432

Review 6.  Mode of action of fluoroquinolones.

Authors:  D C Hooper
Journal:  Drugs       Date:  1999       Impact factor: 9.546

7.  Quinolone pharmacokinetics and metabolism.

Authors:  H Lode; G Höffken; M Boeckk; N Deppermann; K Borner; P Koeppe
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

8.  Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells.

Authors:  M E Cavet; M West; N L Simmons
Journal:  Br J Pharmacol       Date:  1997-08       Impact factor: 8.739

9.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

10.  Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers.

Authors:  N M Griffiths; B H Hirst; N L Simmons
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

View more
  5 in total

1.  Changes in antibiotic distribution due to pancreatitis.

Authors:  Kent J Fanning; Thomas A Robertson; Johannes B Prins; Michael S Roberts
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

2.  Sotalol permeability in cultured-cell, rat intestine, and PAMPA system.

Authors:  Wei Liu; Hideaki Okochi; Leslie Z Benet; Suo-Di Zhai
Journal:  Pharm Res       Date:  2012-02-14       Impact factor: 4.200

3.  Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification.

Authors:  Tuba Incecayir; Yasuhiro Tsume; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-02-04       Impact factor: 4.939

4.  Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats.

Authors:  Anallely López-Yerena; Anna Vallverdú-Queralt; Raf Mols; Patrick Augustijns; Rosa M Lamuela-Raventós; Elvira Escribano-Ferrer
Journal:  Pharmaceutics       Date:  2020-02-05       Impact factor: 6.321

5.  Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling.

Authors:  Felix Huth; Hilmar Schiller; Yi Jin; Birk Poller; Carole Schuhler; Wendy Weis; Ralph Woessner; Anton Drollmann; Peter End
Journal:  Clin Transl Sci       Date:  2021-08-25       Impact factor: 4.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.